{"id":55829,"date":"2026-01-29T21:57:19","date_gmt":"2026-01-29T13:57:19","guid":{"rendered":"https:\/\/flcube.com\/?p=55829"},"modified":"2026-02-26T16:11:55","modified_gmt":"2026-02-26T08:11:55","slug":"fosun-pharma-licenses-hpv-dna-drug-vgx-3100-from-apollobio-for-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55829","title":{"rendered":"Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China"},"content":{"rendered":"\n<p><strong>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA:\u202f600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG:\u202f2196<\/a>) announced a licensing agreement with <strong>ApolloBio Corp.<\/strong>, securing <strong>exclusive commercialization rights<\/strong> for <strong>VGX-3100<\/strong> in <strong>Greater China<\/strong> (mainland China, Hong Kong, Macau, and Taiwan). Fosun Pharma will also assume responsibility for local manufacturing of the therapeutic DNA drug.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-strategic-terms\">Deal Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>ApolloBio Corp. (NEEQ:\u202f430187)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Shanghai Fosun Pharmaceutical (SHA:\u202f600196, HKG:\u202f2196)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>VGX-3100 (therapeutic DNA drug)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Greater China (exclusive)<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Commercialization + local manufacturing<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Cervical high\u2011grade squamous intraepithelial lesions (HSIL, CIN2\/3) from HPV16\/18<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase\u202fIII clinical trials in China<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>DNA plasmids targeting HPV16\/18 E6\/E7 proteins, activating cellular and humoral immunity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-innovation\">Drug Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic DNA Approach:<\/strong> VGX-3100 delivers plasmids encoding HPV16\/18 E6\/E7 antigens, triggering immune\u2011mediated clearance of virus and infected cells<\/li>\n\n\n\n<li><strong>First\u2011in\u2011Class Potential:<\/strong> No approved therapeutic DNA vaccine for cervical precancerous lesions in China; addresses <strong>unmet need<\/strong> in HPV16\/18\u2011related disease<\/li>\n\n\n\n<li><strong>Clinical Progress:<\/strong> Phase\u202fIII trials underway, targeting <strong>HSIL (CIN2\/3)<\/strong> patients<\/li>\n\n\n\n<li><strong>Manufacturing Advantage:<\/strong> Fosun\u2019s local production capability reduces supply chain risk and accelerates market access upon approval<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China HPV Market:<\/strong> Cervical cancer screening programs and rising HPV awareness drive a <strong>\u00a510\u202fbillion+<\/strong> (US$1.4\u202fbillion) therapeutic vaccine market by 2030<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Estimated <strong>1.5\u202fmillion<\/strong> women in Greater China have HSIL from HPV16\/18, representing a sizable target population<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes with surgical interventions (LEEP) and observation; VGX-3100 offers non\u2011invasive alternative with curative intent<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a53\u20135\u202fbillion<\/strong> (US$420\u2013700\u202fmillion) peak annual sales if approved, based on broad screening coverage and vaccination gaps<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Strengthens Fosun\u2019s position in <strong>oncology prevention<\/strong> and <strong>innovative vaccines<\/strong>, complementing its existing women\u2019s health franchise<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Phase\u202fIII data readout expected <strong>2027<\/strong>; NDA submission targeted for <strong>2028<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for VGX-3100. Actual results may differ due to clinical trial outcomes, competitive dynamics, and NMPA review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:\u202f600196, HKG:\u202f2196) announced a licensing agreement with ApolloBio Corp.,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55830,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[153,159,893,892],"class_list":["post-55829","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-apollobio","tag-fosun-pharmaceutical","tag-hkg-2196","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:\u202f600196, HKG:\u202f2196) announced a licensing agreement with ApolloBio Corp., securing exclusive commercialization rights for VGX-3100 in Greater China (mainland China, Hong Kong, Macau, and Taiwan). Fosun Pharma will also assume responsibility for local manufacturing of the therapeutic DNA drug.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55829\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China\" \/>\n<meta property=\"og:description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:\u202f600196, HKG:\u202f2196) announced a licensing agreement with ApolloBio Corp., securing exclusive commercialization rights for VGX-3100 in Greater China (mainland China, Hong Kong, Macau, and Taiwan). Fosun Pharma will also assume responsibility for local manufacturing of the therapeutic DNA drug.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55829\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T13:57:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-26T08:11:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2912.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55829#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55829\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China\",\"datePublished\":\"2026-01-29T13:57:19+00:00\",\"dateModified\":\"2026-02-26T08:11:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55829\"},\"wordCount\":340,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55829#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2912.webp\",\"keywords\":[\"ApolloBio\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55829#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55829\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55829\",\"name\":\"Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55829#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55829#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2912.webp\",\"datePublished\":\"2026-01-29T13:57:19+00:00\",\"dateModified\":\"2026-02-26T08:11:55+00:00\",\"description\":\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:\u202f600196, HKG:\u202f2196) announced a licensing agreement with ApolloBio Corp., securing exclusive commercialization rights for VGX-3100 in Greater China (mainland China, Hong Kong, Macau, and Taiwan). Fosun Pharma will also assume responsibility for local manufacturing of the therapeutic DNA drug.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55829#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55829\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55829#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2912.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2912.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55829#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:\u202f600196, HKG:\u202f2196) announced a licensing agreement with ApolloBio Corp., securing exclusive commercialization rights for VGX-3100 in Greater China (mainland China, Hong Kong, Macau, and Taiwan). Fosun Pharma will also assume responsibility for local manufacturing of the therapeutic DNA drug.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55829","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China","og_description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:\u202f600196, HKG:\u202f2196) announced a licensing agreement with ApolloBio Corp., securing exclusive commercialization rights for VGX-3100 in Greater China (mainland China, Hong Kong, Macau, and Taiwan). Fosun Pharma will also assume responsibility for local manufacturing of the therapeutic DNA drug.","og_url":"https:\/\/flcube.com\/?p=55829","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-29T13:57:19+00:00","article_modified_time":"2026-02-26T08:11:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2912.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55829#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55829"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China","datePublished":"2026-01-29T13:57:19+00:00","dateModified":"2026-02-26T08:11:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55829"},"wordCount":340,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55829#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2912.webp","keywords":["ApolloBio","Fosun Pharmaceutical","HKG: 2196","SHA: 600196"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55829#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55829","url":"https:\/\/flcube.com\/?p=55829","name":"Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55829#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55829#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2912.webp","datePublished":"2026-01-29T13:57:19+00:00","dateModified":"2026-02-26T08:11:55+00:00","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:\u202f600196, HKG:\u202f2196) announced a licensing agreement with ApolloBio Corp., securing exclusive commercialization rights for VGX-3100 in Greater China (mainland China, Hong Kong, Macau, and Taiwan). Fosun Pharma will also assume responsibility for local manufacturing of the therapeutic DNA drug.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55829#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55829"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55829#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2912.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2912.webp","width":1080,"height":608,"caption":"Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55829#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2912.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55829"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55829\/revisions"}],"predecessor-version":[{"id":55832,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55829\/revisions\/55832"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55830"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55829"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55829"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}